<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The optimal use of transcription factors to determine B-lineage specificity in B-<z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) has not been fully investigated </plain></SENT>
<SENT sid="1" pm="."><plain>We undertook an extensive immunohistochemical study of a panel of B-cell transcription factors in B- and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> to evaluate those with the best specificity and sensitivity </plain></SENT>
<SENT sid="2" pm="."><plain>Tissue microarrays were constructed from 34 B-ALL, 19 T-ALL, and 30 Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> samples </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 34 (100%) cases of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> expressed PAX5; 32 (94%), BOB.1; 33 (97%), PU.1; 29 (85%), CD79a; 27 (79%), CD22; 2 (6%), CD20; 9 (26%), OCT-2; and 3 (9%), MUM1 </plain></SENT>
<SENT sid="4" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases were positive for PAX5 (30/30 [100%]), BOB.1 (27/30 [90%]), PU.1 (23/30 [77%]), CD79a (29/30 [97%]), CD22 (14/30 [47%]), CD20 (30/30 [100%]), OCT-2 (23/30 [77%]), and MUM1 (5/30 [17%]) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALLs</z:e> were only positive for PU.1 (15/19 [79%]) and BOB.1 (12/19 [63%]) </plain></SENT>
<SENT sid="6" pm="."><plain>PAX5 demonstrated better specificity for B-lineage determination than BOB.1 and PU.1 and better sensitivity than CD79a, CD22, and CD20 </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that PAX5 has the greatest diagnostic usefulness and lineage determination in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, especially in cases with an inadequate specimen for flow cytometric analysis </plain></SENT>
</text></document>